This company listing is no longer active
Vivoryon Therapeutics Future Growth
Future criteria checks 3/6
Vivoryon Therapeutics is forecast to grow earnings and revenue by 71.8% and 65.1% per annum respectively. EPS is expected to decline by 8.4% per annum. Return on equity is forecast to be -135.7% in 3 years.
Key information
71.8%
Earnings growth rate
-8.4%
EPS growth rate
| Biotechs earnings growth | 35.4% |
| Revenue growth rate | 65.1% |
| Future return on equity | -135.7% |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 20 | 1 | N/A | 48 | 1 |
| 12/31/2023 | 6 | -10 | -16 | -10 | 2 |
| 12/31/2022 | N/A | -13 | -12 | -12 | 2 |
| 12/31/2021 | 11 | -13 | -11 | -11 | N/A |
| 9/30/2021 | 11 | -12 | -11 | -11 | N/A |
| 6/30/2021 | N/A | -21 | -14 | -14 | N/A |
| 3/31/2021 | N/A | -19 | -14 | -14 | N/A |
| 12/31/2020 | N/A | -17 | -15 | -14 | N/A |
| 9/30/2020 | N/A | -15 | -15 | -15 | N/A |
| 6/30/2020 | N/A | -12 | -15 | -15 | N/A |
| 3/31/2020 | N/A | -10 | -13 | -13 | N/A |
| 12/31/2019 | N/A | -8 | -12 | -12 | N/A |
| 9/30/2019 | N/A | -7 | -9 | -9 | N/A |
| 6/30/2019 | N/A | -7 | -6 | -6 | N/A |
| 3/31/2019 | N/A | -7 | -7 | -7 | N/A |
| 12/31/2018 | N/A | -8 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2018 | N/A | -8 | -9 | -9 | N/A |
| 3/31/2018 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2017 | N/A | -8 | -12 | -12 | N/A |
| 9/30/2017 | N/A | -10 | -13 | -13 | N/A |
| 6/30/2017 | N/A | -12 | -14 | -14 | N/A |
| 3/31/2017 | N/A | -13 | -14 | -14 | N/A |
| 12/31/2016 | N/A | -14 | -13 | -13 | N/A |
| 9/30/2016 | N/A | -14 | -13 | -13 | N/A |
| 6/30/2016 | N/A | -13 | -13 | -13 | N/A |
| 3/31/2016 | N/A | -13 | -13 | -13 | N/A |
| 12/31/2015 | N/A | -14 | -12 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 05Y is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Earnings vs Market: 05Y is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 05Y is expected to become profitable in the next 3 years.
Revenue vs Market: 05Y is forecast to have no revenue next year.
High Growth Revenue: 05Y is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 05Y is forecast to be unprofitable in 3 years.